Moth Bean Peptides That Block the Blood Pressure Enzyme: From Lab to Rats

Peptides extracted from moth bean seeds blocked ACE (a key blood pressure enzyme) in the lab and lowered blood pressure by 30 mmHg in hypertensive rats.

Bhadkaria, Amita et al.·International journal of biological macromolecules·2023·Preliminary EvidenceAnimal StudyAnimal Study
RPEP-06736Animal StudyPreliminary Evidence2023RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Animal Study
Evidence
Preliminary Evidence
Sample
Dexamethasone-induced hypertensive rats (in vivo); in vitro enzyme and molecular docking analyses
Participants
Dexamethasone-induced hypertensive rats (in vivo); in vitro enzyme and molecular docking analyses

What This Study Found

Researchers extracted peptides from moth bean seeds using six different enzymes and found that alcalase produced the most effective ACE-inhibiting fragments. The most potent peptide fraction inhibited ACE at just 11.19 ± 0.15 μg/mL. Four specific peptides (IAWDFR, ADLPGLK, DKPWWPK, and AVIPNAPNLR) were identified through mass spectrometry, with molecular docking showing two bind to active sites and two to non-active sites of the ACE molecule.

In live testing, the moth bean protein hydrolysate lowered systolic blood pressure in hypertensive rats from 155 ± 3.13 mmHg (control) to 125 ± 0.76 mmHg — a 30 mmHg reduction.

Key Numbers

ACE inhibition IC50: 11.19 ± 0.15 μg/mL · SBP reduced: 155 → 125 mmHg · 30 mmHg drop · 4 peptides identified

How They Did This

Moth bean seed protein was extracted and hydrolyzed with six enzymes (alcalase, chymotrypsin, flavourzyme, papain, pepsin, trypsin). The most active hydrolysate was purified by FPLC and analyzed by mass spectrometry. Molecular docking simulated peptide binding to ACE. In vivo testing used dexamethasone-induced hypertensive rats.

Why This Research Matters

ACE inhibitor drugs are a cornerstone of blood pressure treatment but come with side effects like dry cough. Finding natural ACE-inhibiting peptides in common food legumes could eventually lead to functional foods or nutraceuticals that help manage blood pressure with fewer side effects.

The Bigger Picture

Food-derived ACE-inhibiting peptides are a growing area of nutraceutical research, with peptides from milk, fish, and soy already well-studied. This work adds moth bean — an affordable, drought-resistant legume — to that list. If the blood pressure effects hold up in human studies, it could support development of bean-based functional foods for cardiovascular health.

What This Study Doesn't Tell Us

This is an animal study — the blood pressure effects were shown in rats with chemically induced hypertension, which may not translate directly to human essential hypertension. The peptides were tested as a hydrolysate mixture rather than as isolated pure peptides in the in vivo portion. No toxicity or long-term safety data was reported.

Questions This Raises

  • ?Would these peptides survive human digestion intact enough to still inhibit ACE?
  • ?How do moth bean ACE-inhibiting peptides compare in potency to those from milk or fish sources?
  • ?Could these peptides be concentrated into a supplement that meaningfully lowers blood pressure in humans?

Trust & Context

Key Stat:
30 mmHg drop Moth bean peptide hydrolysate reduced systolic blood pressure from 155 to 125 mmHg in hypertensive rats
Evidence Grade:
Rated preliminary because this combines in vitro enzyme assays with a small animal study. While the ACE inhibition data and molecular docking are solid, the blood pressure findings are from chemically induced hypertension in rats, which is an early step on the path to clinical relevance.
Study Age:
Published in 2023, this is recent research in the active field of food-derived bioactive peptides. The findings are relevant but still at the preclinical stage.
Original Title:
Purification, molecular docking and in vivo analyses of novel angiotensin-converting enzyme inhibitory peptides from protein hydrolysate of moth bean (Vigna aconitifolia (Jacq.) Màrechal) seeds.
Published In:
International journal of biological macromolecules, 230, 123138 (2023)
Database ID:
RPEP-06736

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / Observational
Case Report / Animal StudyOne case or non-human subjects
This study

Tests effects in animals (usually mice or rats), not humans.

What do these levels mean? →

Frequently Asked Questions

Can eating moth beans lower blood pressure?

This study found that peptides extracted from moth bean protein lowered blood pressure in rats, but that doesn't mean eating whole moth beans would have the same effect. The peptides were concentrated through enzymatic digestion and purification. Human studies would be needed to know if dietary moth beans provide meaningful blood pressure benefits.

How do food-derived ACE inhibitors compare to pharmaceutical ones?

Food-derived ACE-inhibiting peptides are generally much weaker than drugs like lisinopril or enalapril. They're being studied as potential functional food ingredients that might modestly support cardiovascular health, not as replacements for prescribed blood pressure medication.

Read More on RethinkPeptides

Cite This Study

RPEP-06736·https://rethinkpeptides.com/research/RPEP-06736

APA

Bhadkaria, Amita; Narvekar, Dakshita Tanaji; Nagar, D P; Sah, Sangeeta Pilkwal; Srivastava, Nidhi; Bhagyawant, Sameer Suresh. (2023). Purification, molecular docking and in vivo analyses of novel angiotensin-converting enzyme inhibitory peptides from protein hydrolysate of moth bean (Vigna aconitifolia (Jacq.) Màrechal) seeds.. International journal of biological macromolecules, 230, 123138. https://doi.org/10.1016/j.ijbiomac.2023.123138

MLA

Bhadkaria, Amita, et al. "Purification, molecular docking and in vivo analyses of novel angiotensin-converting enzyme inhibitory peptides from protein hydrolysate of moth bean (Vigna aconitifolia (Jacq.) Màrechal) seeds.." International journal of biological macromolecules, 2023. https://doi.org/10.1016/j.ijbiomac.2023.123138

RethinkPeptides

RethinkPeptides Research Database. "Purification, molecular docking and in vivo analyses of nove..." RPEP-06736. Retrieved from https://rethinkpeptides.com/research/bhadkaria-2023-purification-molecular-docking-and

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.